{
  "ticker": "LLY",
  "target_date": "2025-05-15",
  "actual_date": "2025-05-15",
  "collected_at": "2025-12-08T11:46:14.679455",
  "price": {
    "open": 721.57,
    "high": 734.47,
    "low": 708.16,
    "close": 729.1154174804688,
    "volume": 5212900,
    "change_1d_pct": 2.48,
    "change_7d_pct": -5.4,
    "change_30d_pct": -10.38
  },
  "technicals": {
    "rsi_14": 27.38,
    "sma_20": 802.81,
    "sma_50": 800.5,
    "macd": -21.067,
    "macd_signal": -10.471,
    "macd_histogram": -10.596,
    "bb_upper": 915.95,
    "bb_lower": 689.67,
    "price_vs_sma20_pct": -9.18,
    "price_vs_sma50_pct": -8.92,
    "volume_ratio": 1.0
  },
  "fundamentals": {
    "market_cap": 892162736128,
    "pe_ratio": 48.760902,
    "forward_pe": 43.919243,
    "price_to_book": 37.470257,
    "price_to_sales": 15.01457,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.5,
    "pct_from_52w_low": 59.55
  },
  "macro": {
    "spy": {
      "price": 587.09,
      "change_1d_pct": 0.49,
      "change_7d_pct": 5.22
    },
    "vix": {
      "level": 17.83,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.45
    },
    "dollar_index": {
      "level": 100.88
    },
    "gold": {
      "price": 3220.7
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "BlackRock Capital Appreciation V.I. Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1747353060,
      "summary": "BlackRock Capital Appreciation V.I. Fund posted a return of -10.69% (Class I shares) for the first quarter of 2025. Read more here.",
      "url": "https://finnhub.io/api/news?id=1b2fa00a0a5e733ed23500a860dbfee3c7150df1d4547497dc0463c73f91fa0a"
    },
    {
      "headline": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
      "source": "SeekingAlpha",
      "datetime": 1747342160,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=642997139796d1ec22e42b910d04d46a39c8d9d41e0d602b85609a2eb28d3a9d"
    },
    {
      "headline": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
      "source": "SeekingAlpha",
      "datetime": 1747330084,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b756f83ede5a952ac1cd88a2f2bfbfaeb147a2d8042368572bb7e00b02603f9d"
    },
    {
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "source": "MarketWatch",
      "datetime": 1747326660,
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d5939b8a60615cde95b636452c65a0f1317ff7f88253b932985a67c733cf479c"
    },
    {
      "headline": "Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-Editing Therapeutics",
      "source": "Finnhub",
      "datetime": 1747320915,
      "summary": "May 15 - Rznomics: * RZNOMICS ENTERS GLOBAL LICENSING AGREEMENT WITH ELI LILLYFORRNA-EDITING THERAPEUTICS * RZNOMICS: UPFRONT PAYMENT WAS NOT DISCLOSED ...",
      "url": "https://finnhub.io/api/news?id=8954149dd0a4cd1c418caf3cc80b8cd1e9932145d614d301f82380cb7ef57b2e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-05-15",
      "description": "xslF345X05/wk-form4_1747340244.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000144/xslF345X05/wk-form4_1747340244.xml"
    },
    {
      "form": "8-K",
      "date": "2025-05-08",
      "description": "lly-20250505.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000138/lly-20250505.htm"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746476222.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000134/xslF345X05/wk-form4_1746476222.xml"
    },
    {
      "form": "10-Q",
      "date": "2025-05-01",
      "description": "lly-20250331.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/lly-20250331.htm"
    },
    {
      "form": "8-K",
      "date": "2025-05-01",
      "description": "lly-20250501.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}